Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Topics:
Rheumatology
•
General Rheumatology
•
Infectious disease
•
Shingles vaccination
Would you advise an immunocompromised patient that developed a dermatomal rash after the first recombinant zoster vaccine to receive the second dose?
Related Questions
How do you approach management of patients with active RA and recurrent non-severe C.diff?
What is the optimal timing for Zoster vaccine administration for a patient who recently recovered from herpes zoster infection and is now planning to start B-cell depletion therapy?
When is it safe to resume DMARDs in a patient who was diagnosed with active TB and started on treatment?
How do you approach treatment of RA with methotrexate in a patient with treated Hepatitis C and normal liver function?
Do you consider anti-viral prophylaxis in patients taking JAK inhibitors who have recurrent uncomplicated Zoster infection, but would prefer not changing therapy?
What is your approach to working up diarrhea in an immunocompromised patient?
How do you approach the workup for a patient with persistently elevated inflammatory markers (CRP and ESR) whose history and exam do not point to a clear cause?
When considering the use of DOACs in APLS, does the number of positive APLS antibodies influence your decision?
How would you approach the use of JAK inhibitors in a patient with stable RA who is now starting treatment for pulmonary MAC infection?
Is rituximab for refractory ITP contraindicated in the setting of an active COVID infection, particularly in a patient with asymptomatic COVID?
